Leverages drug target to develop and commercialize therapies for auto-immune diseases
Investors 1
Mentions in press and media 5
| Date | Title | Description |
| 26.03.2025 | Avotres Inc. Founder and CSO, Dr. Hong Jiang Presented at the 7th Treg-Directed Therapies Summit | Dr. Hong Jiang presented at 7th Treg-Directed Therapies Summit. BOSTON, MA, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- Avotres proudly announces the successful presentation, titled as “Analyzing the Q/E CD8+ Treg Pathway to Unlock ... |
| 25.06.2024 | AVT001 Phase I/II Clinical Trial 1 Year Data in Type 1 Diabetes is Published | From Breakthrough Discovery to Clinical Proof of Concept CEDAR KNOLLS, NJ, USA, June 25, 2024 /EINPresswire.com/ -- Avotres Inc. in collaboration with Joslin Diabetes Center, a Harvard Medical School affiliate, have reported one year data o... |
| 19.07.2023 | Avotres Presents Clinical Data for AVT001, a Novel Dendritic Cell Vaccine for Treatment of Type 1 Diabetes at ADA2023 | • AVT001 is an investigational autologous dendritic cell-based vaccine for the treatment of new onset T1D CEDAR KNOLLS, NJ, UNITED STATES, July 19, 2023/EINPresswire.com/ -- Avotres Inc., a clinical stage biotechnology company developing tr... |
| 09.12.2022 | Avotres Announces Achieving Primary Endpoint of its Phase 1/2 Clinical Trial of AVT001 in Patients with Type 1 Diabetes | - AVT001 met its primary endpoints (safety) and demonstrated a strong efficacy signal at the primary readout of its phase 1/2 study for Type 1 Diabetes CEDAR KNOLLS, NJ, UNITED STATES, December 9, 2022 /EINPresswire.com/ -- Avotres Inc., a ... |
| - | Avotres | “Avotres Inc. is a private biotechnology company developing breakthrough therapeutic solutions for incurable immunologically mediated disorders.” |
Reviews 0
